Regarding potential therapeutic consequences, CAIX-based agents like the CAIX-specific monoclonal antibody girentuximab have been evaluated in a phase III clinical trials in high-risk renal cell carcinoma [25]. The gene discussed is CA9; the disease is renal cell carcinoma.